Early evidence suggests that while some cancers in PHIV respond similarly to ICIs as in HIV-negative individuals, differences in tumor microenvironment composition, such as lower CD8+ T-cell infiltration or differential PD-L1 expression, might contribute to varied therapeutic outcomes. Here, CD8A is linked to neoplasm.